Cariprazine Versus Placebo for Social Anxiety Disorder
Status:
Not yet recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
The proposed study is a 12 week double-blind, placebo-controlled trial to examine the
efficacy, safety, and tolerability of Vraylar® (cariprazine) in the treatment of patients
with Social Anxiety Disorder (SAD), as defined by the Diagnostic and Statistical Manual of
Mental Disorders, 5th edition (DSM-5). Subjects will be randomized to one of two treatment
arms (placebo or Vraylar® 1.5 mg/day) in a 1:1 ratio. The study will be done at a single
clinical research site.